CDH1 and prostate adenocarcinoma: Lower E-cadherin expression is reported to be related to worse overall-survival and disease-free survival (HR 3.69, 95%CI 1.18–11.50; HR 5.90, 95%CI 1.40–24.81) in the pT3b group of prostatic adenocarcinoma in the study of Ferreira et al. [15].